Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：董事会提名委员会关于第四届董事会职工代表董事候选人任职资格的审查意见
Board/Management Information Classification · 85% confidence The document is a formal announcement by the board’s Nomination Committee reviewing and approving the qualification of a candidate for an employee representative director position. It relates directly to board composition and director nominations, fitting the category for board/management information.
2026-05-22 Chinese
美迪西：股东减持计划时间届满暨减持股份结果公告
Major Shareholding Notification Classification · 82% confidence The document is an official stock exchange announcement of a major shareholder’s share reduction plan expiration and actual reduction results, detailing pre- and post-sale holdings. It reports a change in significant share ownership levels by a consistent acting group above the 5% threshold. This fits the “Major Shareholding Notification” category (MRQ).
2026-05-22 Chinese
美迪西：2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the 2025 Annual General Meeting resolutions, providing details on meeting attendance, each proposal voted on, and the voting results. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-05-14 Chinese
北京市安理律师事务所关于上海美迪西生物医药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 81% confidence The document is a legal opinion (“法律意见书”) issued by a law firm regarding the convening, procedural compliance, attendees’ qualifications, and voting results of the company’s 2025 Annual General Meeting. It is an attestation/certification letter prepared for regulatory submission, not the AGM materials themselves, not the actual meeting minutes from the company, nor an announcement of voting results issued by the company. Under the classification rules, such a standalone legal opinion or officer certification is categorized as a Regulatory Filing (RNS).
2026-05-14 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 92% confidence The document is a ‘持续督导跟踪报告’ prepared by the sponsor (广发证券) under listing rules to report its ongoing compliance supervision activities over the listed company. It is not the company’s annual or interim financial report, nor an earnings release, proxy statement, or management discussion prepared by the issuer. Rather, it is a regulatory/compliance filing by the sponsor, with no specific slot in the menu. As such, it falls into the catch-all Regulatory Filings category.
2026-05-11 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司向特定对象发行股票之保荐总结报告书
Share Issue/Capital Change Classification · 80% confidence The document is a formal sponsor’s summary report (“保荐总结报告书”) issued by Guangfa Securities regarding Shanghai Medicilon’s private placement of shares (“向特定对象发行股票”). It reviews the continuous supervision, fund usage, approval dates, and sponsor opinions—clearly tied to a share issuance transaction. Under our taxonomy, announcements or reports concerning share issuance and capital structure changes fall under Share Issue/Capital Change (SHA).
2026-05-11 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.